• 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br References br P P Reid W


    [3] P.P. Reid, W.D. Compton, J.H. Grossman, G. Fanjiang, Building a Better Delivery System: A New Engineering/Health Care Partnership, 1st ed., National Academies Press, 2005.
    [9] H. Schättler, U. Ledzewicz, Optimal Control for Mathematical Models of Cancer Therapies, 1st ed., Springer, 2015.
    [11] D.V. Caiado, J.M. Lemos, Optimal control for cancer therapy design, 23rd Mediterranean Conference on Control and Automation.
    [14] P. Oliveira, J.P. Hespanha, J.M. Lemos, T. Mendonc¸ a, Supervised multi-model adaptive control of neuromuscular blockade with off-set compensation, in: Proceedings of the European Control Conference 2009, Budapest, Hungary, August 23–26, 2009, 2009.
    [17] J.M. Lemos, P.S. Oliveira, J.S. Marques, T.F. Mendonc¸ a, Clustering in supervised multi-model adaptive control applied to neuromuscular blockade, in: Proceedings of the 15th IFAC Symposium on System Identification, Saint-Malo, France, July 6–8, 2009, IFAC, 2009.
    [18] P. Hahnfeldt, D. Panigrahy, J. Folkman, L. Hlatky, Tumor development under angiogenic signalling: a dynamical E-64 of tumor growth, treatment response, and postvascular dormancy, Cancer Res. 59 (1999) 4770–4775.
    [25] H. Mizugaki, N. Yamamoto, H. Murakami, H. Kenmotsu, Y. Fujiwara, Y. Ishida, T. Kawakami, T. Takahashi, Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors, Invest. New Drugs 34 (2016) 596–603.
    [37] K. Narendra, J. Balakrishnan, Improving transient response of adaptive control systems using multiple models and switching, IEEE Trans. Autom. Control 39
    [46] J. MacQueen, Some methods for classification and analysis of multivariate observations, Proc. Fifth Berkeley Symp. on Math. Statist. and Prob., volume 1 (1967) 281–297.
    Contents lists available at ScienceDirect
    Cancer Letters
    journal homepage:
    Original Articles
    Cancer-associated acinar-to-ductal metaplasia within the invasive front of T pancreatic cancer contributes to local invasion
    Shin Kibea, Kenoki Ohuchidaa,∗, Yohei Andoa, Shin Takesuea, Hiromichi Nakayamaa, Toshiya Abea, Sho Endoa, Kazuhiro Koikawaa, Takashi Okumuraa, Chika Iwamotob, Koji Shindoa, Taiki Moriyamac, Kohei Nakataa, Yoshihiro Miyasakaa, Masaya Shimamotod, Takao Ohtsukaa, Kazuhiro Mizumotod, Yoshinao Odae, Masafumi Nakamuraa,∗∗ a Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    b Department of Advanced Medical Initiatives, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    c Department of Endoscopic Diagnostics and Therapeutics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    d Kyushu University Hospital Cancer Center, Fukuoka, Japan
    e Department of Anatomical Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    Pancreatic cancer
    Tumor microenvironment
    Local invasion
    Acinar atrophy 
    The pancreas is an organ prone to inflammation, fibrosis, and atrophy because of an abundance of acinar cells that produce digestive enzymes. A characteristic of pancreatic cancer is the presence of desmoplasia, in-flammatory cell infiltration, and cancer-associated acinar atrophy (CAA) within the invasive front. CAA is characterized by a high frequency of small ducts and resembles acinar-to-ductal metaplasia (ADM). However, the clinical significance of changes in acinar morphology, such as ADM with acinar atrophy, within the tumor microenvironment remains unclear. Here, we find that ADM within the invasive front of tumors is associated with cell invasion and desmoplasia in an orthotopic mouse model of pancreatic cancer. An analysis of resected human tumors revealed that regions of cancer-associated ADM were positive for TGFα, and that this TGFα expression was associated with primary tumor size and shorter survival times. Gene expression analysis iden-tified distinct phenotypic profiles for cancer-associated ADM, sporadic ADM and chronic pancreatitis ADM. These findings suggest that the mechanisms driving ADM differ according to the specific tissue microenviron-ment and that cancer-associated ADM and acinar atrophy contribute to tumor cell invasion of the local pan-creatic parenchyma.
    1. Introduction
    Pancreatic cancer remains one of the most lethal human cancers among all malignancies, with a 5-year survival rate of approximately 8% [1]. Pancreatic cancer is predicted to become the second leading cause of cancer mortality by the year 2030 [2]. Because the disease is commonly diagnosed at a late stage, less than 20% of patients present with localized, potentially curable tumors. Even after potentially curative resection, most patients will eventually have local recurrence. The biology of pancreatic cancer contributes to early recurrence and metastasis, and resistance to chemotherapy and radiotherapy [3]. Un-derstanding the mechanisms underlying each phase of pancreatic cancer progression: initiation, invasion and metastasis, is therefore